Previous 10 | Next 10 |
2024-03-12 11:00:22 ET BioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Conference Call March 12, 2024 8:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer Vince O'Neill - Chief of Product and Development Medical Officer Richard Steinhart - Chi...
2024-03-12 07:02:27 ET More on BioXcel Therapeutics UBS cuts BioXcel to neutral; cites regulatory issues, financing BioXcel Therapeutics announces termination of proposed public offering Seeking Alpha’s Quant Rating on BioXcel Therapeutics Historical e...
Koninklijke KPN NV (KKPNF) is expected to report for Q4 2023 ECA Marcellus Trust I Unit (ECTM) is expected to report for Q4 2023 San Juan Basin Royalty Trust (SJT) is expected to report for Q4 2023 Avenir Wellness Solutions Inc (AVRW) is expected to report for Q4 2023 Carmell Corp...
Provides update on two late-stage clinical programs for BXCL501 for potential treatment of agitation Recently completed meetings with U.S. Food and Drug Administration for TRANQUILITY and SERENITY programs C onference call and webcast set for 8:00 a.m. ET ...
2024-03-11 12:05:56 ET More on BioXcel Therapeutics UBS cuts BioXcel to neutral; cites regulatory issues, financing BioXcel Therapeutics announces termination of proposed public offering Seeking Alpha’s Quant Rating on BioXcel Therapeutics Historical e...
2024-03-11 05:50:46 ET More on related stocks: Oracle Q3 Earnings Preview: Cloud Computing Business In Focus Blink Charging: EV Tailwinds Offer A Path To Profitability In 2025 Ulta Beauty: We Are Not Adding To Our Position Before The Earnings Release (Rating Downgrad...
NEW HAVEN, Conn., March 01, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full y...
2024-02-21 11:03:58 ET More on BioXcel Therapeutics BioXcel Therapeutics announces termination of proposed public offering BioXcel stock climbs on FDA fast track designation for prostate cancer therapy Seeking Alpha’s Quant Rating on BioXcel Therapeutics ...
PALM BEACH, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Recent reports project that the anal cancer market will continue its recent growth through 2030. An article on the MD Anderson website. It said: “More than 8,000 people in the U.S. are diag...
2024-02-13 12:42:27 ET DENVER, Colo., Feb. 13, 2024 ( www.247marketnews.com )- Today’s big trades include (NASDAQ:OMH), (AMEX:AULT), (NASDAQ:BMR), (NASDAQ:BGLC), (NASDAQ:BTAI), (NASDAQ:LIAN) Ohmyhome (NASDAQ: OMH ) is well below today’s $6.00 high, trading at $2.81...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Advancing TRANQUILITY and SERENITY program plans for two pivotal Phase 3 trials to expand BXCL501 market potential in acute treatment of agitation Strengthened intellectual property portfolio for BXCL501 with grant of two new patents, in Japan and the U.S. Completed $25 million re...